SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Company Response from BioRestorative Therapies, (BRTX) — Dec 8, 2025

BioRestorative Therapies, Inc.
Date: Dec. 8, 2025 · CIK: 0001505497 · Accession: 0001021771-25-000150

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-291623

Date
December 8, 2025
Author
President and Chief Executive Officer
Form
CORRESP
Company
BioRestorative Therapies, Inc.

Letter

Re:

BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747

December 8, 2025

VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549

BioRestorative Therapies, Inc. Registration Statement on Form S-1 Filed November 18, 2025 File No. 333-291623

Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioRestorative Therapies, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on December 10, 2025, or as soon thereafter as practicable. The Registrant hereby authorizes Fred Skolnik, an attorney with the Registrant’s outside legal counsel, Certilman Balin Adler & Hyman, LLP, to orally modify or withdraw this request for acceleration. The Registrant hereby acknowledges that:

•

should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

•

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

•

the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Skolnik at (516) 476-7486. Please also provide a copy of the Commission’s order declaring the Registration Statement on Form S-1 effective to Mr. Skolnik via email at fskolnik@certilmanbalin.com and via mail at Certilman Balin Adler & Hyman, LLP, 90 Merrick Avenue, 9 th Floor, East Meadow, NY 11554.

Very truly yours,
/ s/ Lance Alstodt
Lance Alstodt
President and Chief Executive Officer

Show Raw Text
CORRESP
 1
 filename1.htm

 BioRestorative Therapies, Inc.
 40 Marcus Drive, Suite One
 Melville, New York 11747

 December 8, 2025

 VIA EDGAR
 U.S. Securities and Exchange Commission
 Division of Corporation Finance
 100 F Street, NE
 Washington, DC 20549

 Re:

 BioRestorative Therapies, Inc.
 Registration Statement on Form S-1
 Filed November 18, 2025
 File No. 333-291623

 Ladies and Gentlemen:
 Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioRestorative Therapies, Inc. (the “Registrant”)
 hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on December 10, 2025, or as soon thereafter as practicable.  The Registrant hereby authorizes Fred Skolnik, an
 attorney with the Registrant’s outside legal counsel, Certilman Balin Adler & Hyman, LLP, to orally modify or withdraw this request for acceleration.
 The Registrant hereby acknowledges that:

 •

 should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
 the Commission from taking any action with respect to the filing;

 •

 the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full
 responsibility for the adequacy and accuracy of the disclosure in the filing; and

 •

 the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the
 federal securities laws of the United States.

 The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Skolnik at
 (516) 476-7486.  Please also provide a copy of the Commission’s order declaring the Registration Statement on Form S-1 effective to Mr. Skolnik via email at fskolnik@certilmanbalin.com
 and via mail at Certilman Balin Adler & Hyman, LLP, 90 Merrick Avenue, 9 th Floor, East Meadow, NY 11554.

 Very truly yours,

 / s/ Lance Alstodt
 Lance Alstodt
 President and Chief Executive Officer

 cc:   Certilman Balin Adler & Hyman, LLP